type 2 diabetes and semaglutide Frontiers MDedge - Patients with Type

In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation

Final Thought: A Canadian Case Study in Market Exclusivity for Innovative Drugs This case study highlights the importance of securing a patent portfolio in Canada to utilize the patent linkage system, and other regulatory tools, to delay entry of generic competitors, which inevitably affects pricing across North America

This is unusual for peptides, which are typically degraded in the gastrointestinal tract

If you compare this to providers like Direct Meds or Amino Amigos , which offer consistent pricing without dramatic jumps, the Maximus model starts to look less appealing for long-term use